Clinical trialObservationalWithdrawn
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
- Outcome
- Stopped earlyTrial terminated - Nanoscale Company out of business (Business decision)
- Phase
- Observational
- Status
- Withdrawn
- Study type
- Observational
- Planned start
- October 2012
- Planned end
- February 2013
- Enrollment
- 0 participants
- Sites
- 0
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 16 May 2013
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion
Arm public domain (ClinicalTrials.gov)
pancreatic cancer (): This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: Inclusion Criteria for Pancreatic Cancer Patients: * Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis. * Patients will have had no prior treatment or surgery Inclusion Criteria for Healthy Subjects: * Subjects will have no prior history of any cancer Exclusion Criteria: Exclusion Criteria for Pancreatic Cancer Patients * Any prior treatment for pancreatic cancer * Poorly controlled diabetes Exclusion Criteria for Healthy Subjects * Poorly controlled diabetes
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 0 participants (actual).
Why stopped public domain (ClinicalTrials.gov)
Trial terminated - Nanoscale Company out of business